Experience in genetic testing of hypertrophic cardiomyopathy using nanopore DNA sequencing

Experience in genetic testing of hypertrophic cardiomyopathy using nanopore DNA sequencing

Aim. To investigate the application of the Oxford Nanopore Technologies’ third generation sequencing for the genetic testing of hypertrophic cardiomyopathy.Material and methods. The study involved 12 patients with hypertrophic cardiomyopathy aged 18 to 67 years (women, 9; men, 3). Using the PCR barc...

Full description

Bibliographic Details
Main Authors: R. R. Salakhov, M. V. Golubenko, E. N. Pavlukova, A. N. Kucher, N. P. Babushkina, N. R. Valiahmetov, A. V. Markov, E. O. Belyaeva, A. F. Kanev, M. S. Nazarenko
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2021-11-01
Series:Российский кардиологический журнал
Subjects:
hypertrophic cardiomyopathy
monomolecular sequencing
oxford nanopore technology
myh7
mybpc3.
Online Access:https://russjcardiol.elpub.ru/jour/article/view/4673

Internet

https://russjcardiol.elpub.ru/jour/article/view/4673

Similar Items